UNCY vs. XLO, VYNE, CASI, EYEN, GANX, LEXX, CARA, HCWB, OCUP, and SNSE Should you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Xilio Therapeutics (XLO), VYNE Therapeutics (VYNE), CASI Pharmaceuticals (CASI), Eyenovia (EYEN), Gain Therapeutics (GANX), Lexaria Bioscience (LEXX), Cara Therapeutics (CARA), HCW Biologics (HCWB), Ocuphire Pharma (OCUP), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical preparations" industry.
Xilio Therapeutics (NASDAQ:XLO ) and Unicycive Therapeutics (NASDAQ:UNCY ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings, analyst recommendations and community ranking.
Unicycive Therapeutics has a consensus price target of $5.30, suggesting a potential upside of 409.62%. Given Xilio Therapeutics' higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Xilio Therapeutics.
In the previous week, Unicycive Therapeutics had 7 more articles in the media than Xilio Therapeutics. MarketBeat recorded 11 mentions for Unicycive Therapeutics and 4 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of -0.63 beat Unicycive Therapeutics' score of -0.73 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.
Unicycive Therapeutics received 8 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Xilio Therapeutics an outperform vote while only 65.52% of users gave Unicycive Therapeutics an outperform vote.
54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 4.6% of Xilio Therapeutics shares are held by insiders. Comparatively, 42.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Xilio Therapeutics has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500.
Xilio Therapeutics' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.
Unicycive Therapeutics has higher revenue and earnings than Xilio Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary Unicycive Therapeutics beats Xilio Therapeutics on 11 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Unicycive Therapeutics Competitors List
Related Companies and Tools
